Prime Medicine Inc (PRME) financials
Prime Medicine revenue and earnings by year
Prime Medicine's revenue was $4.63 million in the fiscal year to December 31, 2025, up 55.3% from the year before. Net income was -$201 million, -4342.4% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2020 |
|---|---|---|---|
| Revenue | 5 | 3 | 5 |
| Revenue growth | 55.3% | -42.7% | — |
| Operating income | -208 | -202 | -1 |
| Operating margin | -4498.1% | -6787.4% | -17.9% |
| Net income | -201 | -196 | -3 |
| Net margin | -4342.4% | -6566.6% | -65.5% |
| Diluted EPS | -$1.35 | -$1.65 | — |
| Free cash flow | -167 | -130 | -6 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open PRME in Markets.
See also: PRME returns
No forecast, no recommendation. This page describes Prime Medicine Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.